D. E. Shaw & Co., Inc. Vertex Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 355,458 shares of VRTX stock, worth $167 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

355,458

Previous 212,981 66.9%

Holding current value

$167 Million

Previous $86.7 Million 71.46%

% of portfolio

0.13%

Previous 0.08%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $58.1 Million - $63.6 Million	142,477 Added 66.9%	355,458 $149 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $15.1 Million - $18.1 Million	-44,012 Reduced 17.13%	212,981 $86.7 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $1.77 Million - $1.9 Million	5,235 Added 2.08%	256,993 $89.4 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $14.7 Million - $16.5 Million	46,826 Added 22.85%	251,758 $88.6 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $26.7 Million - $30.5 Million	94,399 Added 85.4%	204,932 $64.6 Million

Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $2.21 Million - $2.48 Million	-7,720 Reduced 6.53%	110,533 $31.9 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $43.9 Million - $49 Million	-160,491 Reduced 57.58%	118,253 $34.2 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $109 Million - $136 Million	-465,504 Reduced 62.55%	278,744 $78.5 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $61.3 Million - $72.3 Million	-277,075 Reduced 27.13%	744,248 $194 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $123 Million - $155 Million	-693,311 Reduced 40.43%	1,021,323 $224 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $170 Million - $190 Million	937,619 Added 120.67%	1,714,634 $311 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $43.2 Million - $50.9 Million	230,391 Added 42.15%	777,015 $157 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $67.8 Million - $79.1 Million	-327,724 Reduced 37.48%	546,624 $117 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $108 Million - $144 Million	523,210 Added 149.0%	874,348 $207 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $52 Million - $61.6 Million	203,308 Added 137.53%	351,138 $95.6 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $33.7 Million - $44.2 Million	-149,357 Reduced 50.26%	147,830 $42.9 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $15.3 Million - $19 Million	-76,786 Reduced 20.53%	297,187 $70.7 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $54.1 Million - $72.7 Million	-324,695 Reduced 46.47%	373,973 $81.9 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $28.5 Million - $32 Million	-171,241 Reduced 19.68%	698,668 $118 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $21.9 Million - $25.4 Million	-133,320 Reduced 13.29%	869,909 $160 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $27.1 Million - $32.2 Million	-165,372 Reduced 14.15%	1,003,229 $185 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $14.7 Million - $18.6 Million	-96,755 Reduced 7.65%	1,168,601 $194 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $27.5 Million - $31.6 Million	163,766 Added 14.87%	1,265,356 $244 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $20.8 Million - $24.2 Million	142,529 Added 14.86%	1,101,590 $187 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $81.8 Million - $95.5 Million	539,411 Added 128.54%	959,061 $156 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $13.1 Million - $14.9 Million	95,561 Added 29.49%	419,650 $62.9 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $48 Million - $52.6 Million	324,089	324,089 $49.3 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account